LABORATORY RESEARCH SNAI1 Is Critical for the Aggressiveness of Prostate Cancer Cells with Low E-Cadherin Researchers examined the role of two epithelial-to-mesenchymal transition regulators, the adherens junction protein E-cadherin and its transcriptional repressor SNAI1, in regulating the aggressiveness of prostate cancer cells. [Mol Cancer] Abstract | Full Article Androgen Receptor Promotes the Oncogenic Function of Overexpressed Jagged1 in Prostate Cancer by Enhancing Cyclin B1 Expression via Akt Phosphorylation Androgen receptor was found to promote the oncogenic function of Jagged1 to enhance cell proliferation rate by comparing four prostate cancer cell lines, LNCaP, LAPC4, DU145 and PC3. [Mol Cancer Res] Abstract Preclinical Pharmacology of FL442, a Novel Nonsteroidal Androgen Receptor Modulator The preclinical profiles of two potent compounds of recently published cycloalkane[d]isoxazole pharmacophore-based androgen receptor (AR) modulators, FL442 and its nitro analog FL425, were explored to evaluate their druggability for the treatment of AR dependent prostate cancer. [Mol Cell Endocrinol] Abstract Identification of an Anabolic Selective Androgen Receptor Modulator that Actively Induces Death of Androgen-Independent Prostate Cancer Cells Researchers screened 3000 selective androgen receptor (AR) modulators for the ability to arrest the androgen-independent growth of AR(+) 22Rv1 and LNCaP prostate cancer cells but not AR(-) PC3 or DU145 cells. [J Steroid Biochem Mol Biol] Abstract Pomegranate Extracts Impact the Androgen Biosynthesis Pathways in Prostate Cancer Models In Vitro and In Vivo Scientists investigated the effects of pomegranate extracts and their ability to inhibit androgen biosynthesis using prostate cancer cell lines in vitro as well as the PTEN knockout mouse model representing prostate cancer. [J Steroid Biochem Mol Biol] Abstract Apigenin Induces Apoptosis by Targeting Inhibitor of Apoptosis Proteins and Ku70-Bax Interaction in Prostate Cancer Treatment of androgen-refractory human prostate cancer PC-3 and DU145 cells with apigenin resulted in dose-dependent suppression of XIAP, c-IAP1, c-IAP2 and survivin protein levels. [Apoptosis] Abstract Shikonin Inhibits the Growth of Human Prostate Cancer Cells via Modulation of the Androgen Receptor Researchers observed that shikonin decreased the expression of androgen receptor at both the mRNA and the protein levels in LNCaP and 22RV1 human prostate cancer cells. [Int J Oncol] Abstract Zyflamend, a Polyherbal Mixture, Down Regulates Class I and Class II Histone Deacetylases and Increases p21 Levels in Castrate-Resistant Prostate Cancer Cells CWR22Rv1 cells, a castrate-resistant prostate cancer cell line, were treated with Zyflamend and the expression of class I and II histone deacetylases, along with their downstream target the tumor suppressor gene p21, was investigated. [BMC Complement Altern Med] Abstract | Full Article CLINICAL RESEARCH Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk The Selenium and Vitamin E Cancer Prevention Trial found no effect of selenium supplementation on prostate cancer risk but a 17% increased risk from vitamin E supplementation. This case-cohort study investigates effects of selenium and vitamin E supplementation conditional upon baseline selenium status. [J Natl Cancer Inst] Abstract | Press Release Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients with Skeletal Metastases: Results from SWOG 0421 Researchers prospectively evaluated the prognostic and predictive value of bone biomarkers in sera from castration-resistant prostate cancer patients treated on a placebo-controlled Phase III trial of docetaxel with or without the bone targeted endothelin-A receptor antagonist atrasentan (SWOG S0421). [J Natl Cancer Inst] Abstract |